Role of infectious agents in systemic rheumatic diseases

Clinical and Experimental Rheumatology

Volumn 26, Issue 1 SUPPL. 48, 2008, Pages

  Amital, Howard ^a   Govoni, Marcello ^b   Maya, Ram ^a   Meroni, Pier Luigi ^c   Ori, Barzilai ^a   Shoenfeld, Yehuda ^a   Tincani, Angela ^d   Trotta, Francesco ^b   Sarzi Puttini, Piercarlo ^e   Atzeni, Fabiola ^e  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Antiphospholipid syndrome; H. pylori; Infections; Rheumatoid arthritis; SAPHO syndrome

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; BETA2 GLYCOPROTEIN 1; COTRIMOXAZOLE; MACROLIDE; MINOCYCLINE; TETRACYCLINE; URSODEOXYCHOLIC ACID; VITAMIN D;

ANTIBODY PRODUCTION; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNE PANCREATITIS; BACTERIAL INFECTION; CELLULAR IMMUNITY; DISEASE ASSOCIATION; ENTERITIS; GASTRITIS; GENETIC SUSCEPTIBILITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOPATHOLOGY; INFECTION; INFECTION RISK; INFLAMMATION; MULTIPLE SCLEROSIS; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROPIONIBACTERIUM; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SAPHO SYNDROME; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIC PURPURA; THYROID DISEASE; VIRUS INFECTION;

AUTOIMMUNE DISEASES; HUMANS; INFECTION; RHEUMATIC DISEASES;

EID: 42649140592     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. MUMCU G, INANC N, YAVUZ S, DIRESKENELI H: The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behçet's disease. Clin Exp Rheumatol 2007; 25 (Suppl. 45): S27-33.
2. ASTRAUSKIENE D, BERNOTIENE E: New insights into bacterial persistence in reactive arthritis. Clin Exp Rheumatol 2007; 25: 470-9.
3. HANNU T, HEDMAN K, HEDMAN L, LEIRISALO-REPO M: Frequency of recent parvovirus infection in patients examined for acute reactive arthritis. A study with combinatorial parvovirus serodiagnostics. Clin Exp Rheumatol 2007; 25: 297-300.
4. NAMBOODIRI AM, ROCCA KM, KUWANA M, PANDEY JP: Antibodies to human cytomegolovirus protein UL83 in systemic sclerosis. Clin Exp Rheumatol 2006; 24: 176-8.
5. ATZENI F, CARRABBA M, DAVIN JC et al.: Skin manifestations in vasculitis and erythema nodosum. Clin Exp Rheumatol. 2006; 24 (Suppl. 40): S60-6.
6. PAGNOUX C, COHEN P, GUILLEVIN L: Vasculitides secondary to infections. Clin Exp Rheumatol 2006; 24 (Suppl. 41): S71-81.
7. BENEDEK TG: The history of bacteriologic concepts of rheumatic fever and rheumatoid arthritis. Semin Arthritis Rheum 2006; 36: 109-23.
8. LAWRENCE JS: Prevalence of rheumatoid arthritis. Ann Rheum Dis 1961; 20: 11-7.
9. VERPOORT KN, PAPENDRECHT-VAN DER VOORT EA, VAN DER HELM-VAN MIL AH et al.: Association of smoking with the constitution of the anti-cyclic citrullinated peptide response in the absence of HLA-DRB1 shared epitope alleles. Arthritis Rheum 2007; 56: 2913-8.
10. BLANK M, KRAUSE I, FRIDKIN M, KELLER N et al.: Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002; 109: 797-804.
11. BLANK M, SHANI A, GOLDBERG I et al.: Libman-Sacks endocarditis associated with antiphospholipid syndrome and infection. Thromb Res 2004; 114: 589-92.
12. SODERLIN MK, KAUTIAINENH, PUOLAKKAINEN M et al.: Infections preceding early arthritis in southern Sweden: A prospective population-based study. J Rheumatol 2003; 30: 459-64.
13. RAMIREZ AS, ROSAS A, HERNANDEZ-BERIAIN JA et al.: Relationship between rheumatoid arthritis and Mycoplasma pneumoniae: A case-control study. Rheumatology (Oxford). 2005; 44: 912-14.
14. BARZILAI O, SHERER Y, RAM M, IZHAKY D, ANAYA JM, SHOENFELD Y: Epstein-Barr virus and cytomegalovirus in autoimmune diseases: Are they truly notorious? A preliminary report. Ann N Y Acad Sci 2007; 1108: 567-77.
15. JORGENSEN KT, WIIK A, PEDERSEN M et al.: Cytokines, autoantibodies, and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis - Case-control study nested in a cohort of Norwegian blood donors. Ann Rheum Dis 2007 Epub ahead of print.
16. ZENTILIN P, SERIOLO B, DULBECCO P et al.: Eradication of Helicobacter pylori may reduce disease severity in rheumatoid arthritis. Aliment Pharmacol Ther 2002; 16: 1291-9.
17. AMEDEI A, BERGMAN MP, APPELMELK BJ et al.: Molecular mimicry between Helicobacter pylori antigens and H+, K+ -adenosine triphosphatase in human gastric autoimmunity. J Exp Med 2003; 198: 1147-56.
18. YAMANISHI S, IIZUMI T, WATANABE E et al.: Implications for induction of autoimmunity via activation of B-1 cells by Helicobacter pylori urease. Infect Immun 2006; 74: 248-56.
19. ARAGONA P, MAGAZZÙ G, MACCHIA G et al.: Presence of antibodies against Helicobacter pylori and its heat-shock protein 60 in the serum of patients with Sjögren's syndrome. J Rheumatol 1999; 26: 1306-11.
20. BIRNIE DH, HOLME ER, MCKAY IC, HOOD S, MCCOLL KE, HILLIS WS: Association between antibodies to heat shock protein 65 and coronary atherosclerosis. Possible mechanism of action of Helicobacter pylori and other bacterial infections in increasing cardiovascular risk. Eur Heart J 1998; 19: 387-94.
21. KUWANA M, IKEDA Y: Helicobacter pylori and immune thrombocytopenic purpura: Unsolved questions and controversies. Int J Hematol 2006; 84: 309-15.
22. VÄRE PO, HEIKIUS B, SILVENNOINEN JA et al.: Seroprevalence of Helicobacter pylori infection in inflammatory bowel disease: Is Helicobacter pylori infection a protective factor? Scand J Gastroenterol 2001; 36: 1295-300.
23. HAREL M, SHOENFELD Y: Predicting and preventing autoimmunity, myth or reality? Ann N Y Acad Sci 2006; 1069: 322-45.
24. LI W, MINOHARA M, SU JJ, MATSUOKA T, OSOEGAWA M, ISHIZU T, KIRA J: Helicobacter pylori infection is a potential protective factor against conventional multiple sclerosis in the Japanese population. J Neuroimmunol 2007; 184: 227-31.
25. SAWALHA AH, SCHMID WR, BINDER SR, BACINO DK, HARLEY JB: Association between systemic lupus erythematosus and Helicobacter pylori seronegativity. J Rheumatol 2004; 31: 1546-50.
26. OHANA M, OKAZAKI K, OSHIMA C et al.: Inhibitory effects of Helicobacter pylori infection on murine autoimmune gastritis. Gut 2003; 52: 1102-10.
27. MERONI PL, RIBOLDI P: Pathogenic mechanisms of antiphospholipid syndrome: A new autoimmune disease. Drug Disc Today: Dis Mech 2004; 1: 309-14.
28. REDECHA PA TILLEY R, TENCATI M et al.: Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007; 110: 2423-31.
29. BERMAN J, GIRARDI G, SALMON JE: TNF-α is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005; 174: 485-90.
30. MARTINEZ DE LA TORRE Y, BURACCHI C, BORRONI EM et al.: Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc Natl Acad Sci USA 2007; 104: 2319-24.
31. FISCHETTI F, DURIGUTTO P, PELLIS V et al.: Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106: 2340-6.
32. PIERANGELI SS, GIRARDI G, VEGA-OSTERTAG M, LIU X, ESPINOLA RG, SALMON J: Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005; 52: 2120-4.
33. CHAOUAT G: The TS1/Th2 paradigm: still important in pregnancy? Semin Immunopathol 2007; 29: 95-113.
34. SHOENFELD Y, BLANK M, CERVERA R, FONT J, RASCHI E, MERONI PL: Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 2006; 65: 2-6.
35. RASCHI E, TESTONI C, BOSISIO D et al.: Role of the MyD88 transduction signalling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003; 101: 3495-500.
36. PIERANGELI SS, VEGA-OSTERTAG ME, RASCHI E et al.: Toll-like receptor and antiphospholipid mediated thrombosis: In vivo studies. Ann Rheum Dis 2007; 66: 1327-33.
37. KAHN MF: SAPHO syndrome. ACR Syllabus October 26, 2003. ACR 67th Annual Scientific Meeting, pag. 27-35.
38. VRN DOORNUM S, BARRACLOUGH D, MCCOLL G, WICKS I: SAPHO: rare or just not recognized? Semin Arthritis Rheum 2000; 30: 70-7.
39. HAYEM G: Valuable lesson from SAPHO syndrome. Joint Bone Spine 2007; 74: 123-6.
40. ROHEKAR G, INMAN RS: Conundrums in nosology: synovitis, acne, pustulosis, hyperostosis and osteitis syndrome and spondylarthritis. Arthritis Care Res 2006; 55: 665-9.
41. COLINA M, LO MONACO A, KHODEIR M, TROTTA F: Propionibacterium acnes and SAPHO syndrome: A case report and literature review. Clin Exp Rheumatol 2007; 25: 457-60.
42. PERRY AL, LAMBERT PA: Propionibacterium acnes. Lett Appl Microbiol 2006; 42: 185-8.
43. STIRLING A, WORTHINGTON T, RAFIQ M, LAMBERT PA, ELLIOTT TSJ: Association between sciatica and Propionibacterium acnes Lancet 2001; 357: 2024-5.
44. JAPPE U, BOIT R, FARRAR MD, INGHAM E, SANDOE J, HOLLAND KT: Evidence for diversity with Propionibacterium acnes: A comparison of the T cell stimulatory activity of isolates from inflammatory acne, endocarditis and the laboratory. J Eur Acad Dermatol Venereol 2004; 18: 450-4.
45. BRUGGEMANN H, HENNE A, HOSTER F et al.: The complete genome sequence of Propionibacterium acnes, a commensal of human skin. Science 2004; 305: 671-3.
46. BRUGGEMANN H: Insights in the pathogenic potential of Propionibacterium acnes from its complete genome. Semin Cutan Med Surg 2005; 24: 67-72.